# Progress Note 04 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frances Burney (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN013-SYN-TD
- Date: 1811-10-19
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harriet Pell, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Review three weeks after right mastectomy. **S**

## History of present illness

Mrs. Burney returns three weeks after a right total mastectomy with sentinel node biopsy. The breast MRI before surgery showed a second 0.8 cm cancer at 7 o'clock, confirmed by MRI-guided biopsy, so with Dr. Marsh she chose mastectomy; she did not want reconstruction. The germline panel showed no pathogenic variant. She had general anesthesia with a pectoral nerve block, was told of each step beforehand, and went home the next morning. Her pain was 2 out of 10 by the third day; she needed no opioid at home and stopped acetaminophen at two weeks. A seroma after drain removal was aspirated once by the surgical team eleven days ago and has not returned. The pathology shows multicentric invasive ductal carcinoma, 2.6 cm and 0.8 cm, grade 2, with clear margins and 0 of 3 sentinel nodes involved. The recurrence score is 13. Dr. Marsh and the breast program's medical oncologist advise five years of anastrozole, with no chemotherapy and no radiation. She has a little numbness under the right arm and is doing her shoulder exercises. Her bone density scan this morning shows low bone mass. **S**

| Element | Detail |
|---|---|
| Interval change | Right total mastectomy and sentinel node biopsy three weeks ago; seroma aspirated once |
| Pathology | pT2(m) pN0(sn), grade 2, margins clear; recurrence score 13 |
| Genetics | No pathogenic germline variant |
| Pain | None at rest; no analgesics now |
| Function | Shoulder flexion improving; walking daily |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy returning |
| Integumentary | Negative | Wound healed; no fluid under the flap |
| Musculoskeletal | Positive | Mild tightness raising the right arm; no bone or joint pain |
| Neurological | Positive | Small patch of numbness under the right arm |
| Genitourinary | Negative | No vaginal dryness or bleeding |
| Psychiatric | Negative | Relieved and sleeping well; PHQ-2 score 1 |

6 systems reviewed. **S**

## Current medications

- Anastrozole 1 mg oral tablet, one tablet by mouth once daily, planned for five years **S**
- Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/76 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 60.9 kg; BMI 23.8 kg/m². All vital signs are synthetic.

Total cholesterol: 214 mg/dL (high); HDL cholesterol: 58 mg/dL; LDL cholesterol: 132 mg/dL (high); Triglycerides: 120 mg/dL; 25-hydroxyvitamin D: 24 ng/mL (low); PHQ-2: 1; Lumbar spine T-score (DXA): -1.4 (low); Femoral neck T-score (DXA): -1.7 (low). All results are synthetic.

## Change since baseline

- PHQ-2: 1 at baseline, 1 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well, cheerful |
| Chest wall | Right mastectomy scar healed; flap flat with no fluid; no erythema |
| Lymph nodes | No axillary or supraclavicular nodes; left breast without masses |
| Extremities | Arm circumference 26.0 cm on each side 10 cm above the elbow; right shoulder flexion 150 degrees, abduction 140 degrees |
| Musculoskeletal | No spinal tenderness; joints without swelling (baseline before anastrozole) |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Multicentric right breast cancer, pT2(m) pN0(sn), hormone receptor positive, HER2 negative, after total mastectomy** (C50.411). Curative surgery with clear margins and negative nodes. A recurrence score of 13 in a postmenopausal woman with node-negative disease means chemotherapy would add no benefit, and radiation is not needed after mastectomy for this stage. **S**
   - Anastrozole 1 mg daily from today for five years.
   - Written survivorship care plan given today: treatment summary, surveillance schedule, side effects of anastrozole, and whom to call.
   - History and examination every three to six months; diagnostic mammogram of the left breast in August, one year after diagnosis; no routine blood tests or body imaging.
2. **Low bone mass on baseline DXA, with vitamin D insufficiency** (M85.80). Lumbar spine T-score -1.4 and femoral neck -1.7, with a 10-year major fracture risk of about 8 percent; anastrozole speeds bone loss. Treatment with a bone medicine is not indicated at this risk. Vitamin D 24 ng/mL. **S**
   - Vitamin D3 1000 units daily and about 1200 mg of calcium a day, mostly from food.
   - Weight-bearing and strength exercise.
   - Repeat DXA in two years, sooner if a fracture occurs.
3. **Anastrozole, starting today** (Z79.811). Baseline: no joint pain, hot flashes, or vaginal dryness. LDL cholesterol 132 mg/dL, to be followed on an aromatase inhibitor. **S**
   - Report joint pain, hot flashes, or vaginal dryness; exercise helps joint aches.
   - Lipids yearly on anastrozole.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Cancer-related history and physical examination | Every 3 to 6 months for the first 3 years | Completed today | Wound healed; no signs of recurrence |
| Laboratory | Surgical pathology and recurrence score | After surgery | Up to date | pT2(m) pN0(sn), margins clear; recurrence score 13 |
| Medication safety | Aromatase inhibitor start | At initiation | Completed today | Anastrozole 1 mg daily started; postmenopausal for eight years, so no ovarian suppression needed |
| Imaging | Bone density (DXA) | Baseline at aromatase inhibitor start, then every 2 years | Completed today | Lumbar spine T-score -1.4, femoral neck -1.7: low bone mass |
| Laboratory | Lipid panel | Periodically on an aromatase inhibitor, by cardiovascular risk | Completed today | Total cholesterol 214, HDL 58, LDL 132, triglycerides 120 mg/dL |
| Laboratory | Calcium and vitamin D adequacy | Ongoing on an aromatase inhibitor | Completed today | 25-hydroxyvitamin D 24 ng/mL, insufficient; vitamin D3 started and calcium from food advised |
| Medication safety | Bone-modifying agent (bisphosphonate or denosumab) | When fracture risk is high, or as adjuvant therapy at higher recurrence risk | Not indicated | Fracture risk about 8 percent and low recurrence risk |
| Examination | Aromatase inhibitor joint pain and musculoskeletal review | Every visit | Completed today | Baseline: no joint pain |
| Survey | Vasomotor and vaginal symptoms | Periodically on endocrine therapy | Completed today | Baseline: none |
| Examination | Lymphedema assessment and risk-reduction counseling | Every visit | Completed today | Arm circumference 26.0 cm on each side; no swelling; counseled on early signs |
| Examination | Lymphedema baseline arm measurements before surgery | Before axillary surgery | Deferred | Not measured at the pre-anesthesia visit as planned, a deviation from the protocol. Today's measurements are equal on both sides, so no swelling has been missed; they serve as the baseline, and arm measurement has been added to the pre-operative checklist |
| Referral | Physical therapy for shoulder movement | After axillary surgery when movement is limited | Referred | Shoulder flexion 150 degrees; four sessions requested |
| Survey | Depression screen (PHQ-2) | At periodic intervals | Completed today | PHQ-2 score 1 |
| Laboratory | Routine blood counts, chemistry, liver tests, and tumor markers | Not recommended in asymptomatic stage I to III survivors | Not indicated | None ordered |
| Imaging | CT, bone scan, or PET for distant spread | Not recommended in asymptomatic survivors | Not indicated | No symptoms |
| Imaging | Diagnostic mammogram of the left breast | Yearly after mastectomy | Due | In August, one year after the diagnostic mammogram |
| Referral | Radiation oncology | After mastectomy when nodes are positive or margins are close | Not indicated | Node-negative with clear margins |
| Imaging | Echocardiogram (LVEF) | During and after trastuzumab | Not indicated | No trastuzumab or anthracycline |
| Self-management | Survivorship care plan and lifestyle counseling | Within one year of treatment; lifestyle every visit | Completed today | Written plan given; 150 minutes of activity a week, strength exercise twice a week once allowed, alcohol at or below one drink a day |

## Goal progress

- Complete diagnosis, staging, and surgery within eight weeks of presentation. Outcome by 1811-10-19: Core biopsy in four days, MRI and a second biopsy within four weeks, mastectomy at seven weeks. **S**
- Surgery under anesthesia with pain controlled without opioids after discharge. Outcome by 1811-10-19: Pain 2 out of 10 by the third day; no opioid after leaving hospital; acetaminophen stopped at two weeks. **S**
- Start adjuvant endocrine therapy with a bone-health plan. Outcome by 1811-10-19: Anastrozole started; baseline DXA shows low bone mass; vitamin D started. **S**
- Regain full right shoulder movement and keep lymphedema risk low. In progress; target 1811-10-29. **S**

## Medication changes

- Started: Anastrozole 1 mg oral tablet, one tablet by mouth once daily, planned for five years **S**
- Started: Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025), National Comprehensive Cancer Network
- American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016), American Cancer Society and American Society of Clinical Oncology
- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026), Aether Forge

## Follow-up

- Physical therapy for the shoulder. Adult preventive visit next week. Survivorship visit in three months. **S**
- Next scheduled visit 1811-10-29: adult preventive visit. **S**
